---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031886"
form_type: "8-K"
ticker: "COCP"
cik: "0001412486"
company_name: "Cocrystal Pharma, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:13.950218+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cocrystal Pharma posts Q2 net loss $5.3M, cash $18.1M; pipeline milestones set

## Summary
- Q2 2024 net loss $5.3M ($0.54/sh) vs Q2 2023 net loss $4.2M ($0.41/sh); R&D spend $4.3M up 54% YoY.
- Cash $18.1M at June 30 from $26.4M at Dec 31; runway expected to fund operations for next 12 months.
- Topline results from Phase 2a influenza A human challenge study (oral CC-42344) expected in 2025.
- In vitro data shows CC-42344 inhibits avian influenza A (H5N1) PB2 protein recently found in U.S. dairy cows.
- Topline Phase 1 results for pan-coronavirus/norovirus oral CDI-988 expected late 2024 / early 2025.

## SEC filing metadata
- accession: 0001493152-24-031886
- form_type: 8-K
- ticker: COCP
- cik: 0001412486
- company_name: Cocrystal Pharma, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1412486/000149315224031886/0001493152-24-031886-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1412486/000149315224031886/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031886
- JSON: https://secwatch.observer/filing/0001493152-24-031886.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031886.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.